AR067047A1 - ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. - Google Patents
ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION.Info
- Publication number
- AR067047A1 AR067047A1 ARP080102596A ARP080102596A AR067047A1 AR 067047 A1 AR067047 A1 AR 067047A1 AR P080102596 A ARP080102596 A AR P080102596A AR P080102596 A ARP080102596 A AR P080102596A AR 067047 A1 AR067047 A1 AR 067047A1
- Authority
- AR
- Argentina
- Prior art keywords
- injection
- acetaminofen
- sodium bicarbonate
- added
- acetaminophen
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title abstract 5
- 238000002347 injection Methods 0.000 title abstract 3
- 239000007924 injection Substances 0.000 title abstract 3
- 229960005489 paracetamol Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 3
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 abstract 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 abstract 1
- 235000019799 monosodium phosphate Nutrition 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1:Una formulacion acuosa estable de acetaminofén para inyeccion, caracterizada porque comprende: a) entre aproximadamente 200,0 mg y aproximadamente 1.400,0 mg de acetaminofén; b) entre aproximadamente 200,0 mg y aproximadamente 10.000,0 mg de manitol para inyeccion; c) entre aproximadamente 0,0 mg y aproximadamente 30,0 mg de fosfato de sodio monobásico; d) entre aproximadamente 0,0 mg y aproximadamente 300,0 mg de povidona; e) entre aproximadamente 2,0 mg y aproximadamente 100,0 mg de L-cisteína, f) una cantidad suficiente de bicarbonato de sodio que se agrega durante la síntesis para ajustar el pH por encima de 8,0; g) luego, se agrega una cantidad suficiente de ácido cítrico luego del bicarbonato de sodio con el objetivo de disminuir el pH hasta entre aproximadamente 6,0 y aproximadamente 40; y h) un volumen de agua para inyeccion hasta un volumen de aproximadamente 100 mL; en donde el mencionado ácido cítrico se agrega luego de la adicion del mencionado bicarbonato de sodio.Claim 1: A stable aqueous formulation of acetaminophen for injection, characterized in that it comprises: a) between about 200.0 mg and about 1,400.0 mg of acetaminophen; b) between about 200.0 mg and about 10,000.0 mg of mannitol for injection; c) between about 0.0 mg and about 30.0 mg of monobasic sodium phosphate; d) between about 0.0 mg and about 300.0 mg of povidone; e) between about 2.0 mg and about 100.0 mg of L-cysteine, f) a sufficient amount of sodium bicarbonate that is added during the synthesis to adjust the pH above 8.0; g) then, a sufficient amount of citric acid is added after sodium bicarbonate in order to lower the pH to between about 6.0 and about 40; and h) a volume of water for injection to a volume of approximately 100 mL; wherein said citric acid is added after the addition of said sodium bicarbonate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92919307P | 2007-06-18 | 2007-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067047A1 true AR067047A1 (en) | 2009-09-30 |
Family
ID=40785551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102596A AR067047A1 (en) | 2007-06-18 | 2008-06-18 | ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR067047A1 (en) |
| WO (1) | WO2009081283A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2464332B2 (en) | 2009-08-13 | 2025-10-15 | Neogen N.V. | Method for producing a storage-stable formulation of paracetamol in aqueous solution |
| US8404748B2 (en) * | 2009-08-13 | 2013-03-26 | Neogen N.V. | Storage-stable formulation of paracetamol in aqueous solution |
| AU2011359032A1 (en) | 2011-02-10 | 2013-08-29 | Neogen N.V. | Storage-stable formulation of paracetamol in aqueous solution |
| ES2414557B1 (en) * | 2012-01-16 | 2014-06-10 | Novocat Farma, S.A. | Aqueous composition of paracetamol for injection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751875B1 (en) * | 1996-08-05 | 1998-12-24 | Scr Newpharm | NOVEL STABLE LIQUID FORMULATIONS BASED ON PARACETAMOL AND THEIR METHOD OF PREPARATION |
| FR2809619B1 (en) * | 2000-06-06 | 2004-09-24 | Pharmatop | NOVEL AQUEOUS FORMULATIONS OF OXIDATION-SENSITIVE ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING THEM |
| CN1582170B (en) * | 2001-12-18 | 2010-05-05 | 联合制药克伦茨蒂斯药物实验室公司 | Parenteral compositions of paracetamol |
| FR2851164B1 (en) * | 2003-02-14 | 2005-04-22 | Xuan Tho Nguyen | INFLATABLE LIQUID FORMULATION OF PARACETAMOL |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
-
2008
- 2008-06-18 WO PCT/IB2008/003925 patent/WO2009081283A2/en not_active Ceased
- 2008-06-18 AR ARP080102596A patent/AR067047A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009081283A2 (en) | 2009-07-02 |
| WO2009081283A3 (en) | 2009-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122516T1 (en) | READY-TO-USE FORMULATIONS OF KETOROLAK | |
| UY27320A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS | |
| PE20071310A1 (en) | LIQUID PHENYLEPHRINE FORMULATIONS | |
| DK1317419T3 (en) | Cyanophenoxycarboxylic acid compounds and compositions to deliver active agents | |
| NZ598839A (en) | Stabilized liquid and lyophilized adamts13 formulations | |
| ES2720954T3 (en) | Statin Stabilized Formulations | |
| AR068598A1 (en) | FLUORIDE ORAL FOAM CARE COMPOSITION FORMING FOAM | |
| EA201170543A1 (en) | PHARMACEUTICAL LIQUID COMPOSITION CONTAINING PARACETAMOL | |
| AR081870A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A PHARMACEUTICALLY ACCEPTABLE AMIDA DERIVATIVE OR SALT OF THE SAME | |
| AR074541A1 (en) | NATURAL SILVER DISINFECTANT COMPOSITIONS | |
| PE20070437A1 (en) | AQUEOUS FORMULATION hFSH | |
| CL2011001225A1 (en) | Pharmaceutical formulation in aqueous solution comprising from 1% to 5% (w / v) of a diclofenac salt, from 3% to 30% (w / v) of at least one fatty acid hydroxide polyoxyalkylene ester and a co- solvent selected from ethanol, propanol, glycerol, propylene glycol among others. | |
| AR034370A1 (en) | A CILOSTAZOL WATERPROOF PHARMACEUTICAL PREPARATION FOR PARENTERAL USE | |
| AR082049A1 (en) | LIQUID FORMULATIONS OF RUPATADINA FUMARATO | |
| AR067048A1 (en) | ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. | |
| MX2009012782A (en) | Formulations for the oral administration of therapeutic agents and related methods. | |
| AR067047A1 (en) | ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. | |
| SE9903831D0 (en) | Formulation of substituted benzimidazoles | |
| PE20011223A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING PEMETREXED AND AN ANTIOXIDANT SUCH AS MONOTHIOGLYCEROL, L-CYSTEINE AND THIOGLICOLIC ACID | |
| EA200300406A1 (en) | PHARMACEUTICAL COMPOSITION OF DRUNEDARON FOR PARENTERAL INTRODUCTION | |
| EA201270745A1 (en) | IMPROVED STABLE AQUEOUS COMPOSITION (E) -4-CARBOXYSTYRYL-4-HLORBENZYLESULPHONE | |
| HRP20140676T1 (en) | Formulations of deoxycholic acid and salts thereof | |
| PE20130374A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING IBUPROFEN | |
| MD3905F1 (en) | Remedy of durable action in the form of gel for treatment of parodentium affections (variants) | |
| AR060869A1 (en) | SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |